




**COHEM**

The 3<sup>rd</sup> World Congress on  
**CONTROVERSIES IN HEMATOLOGY**



**SAVE THE DATES**

**September 11-13, 2014**  
Istanbul, Turkey



[cohem@comtecmed.com](mailto:cohem@comtecmed.com)  
[www.comtecmed.com/cohem](http://www.comtecmed.com/cohem)



# CO-CHAIRPERSONS

Prof. Robin Foà, Italy

Prof. Rüdiger Hehlmann, Germany

Prof. Emili Montserrat, Spain

Prof. Eliezer Rachmilewitz, Israel

Prof. Giuseppe Saglio, Italy

Prof. Charles Schiffer, USA

## LIST OF PRELIMINARY TOPICS

### Non-Malignant Hematology

#### Haemoglobinopathies

- Is there a role for stem cell transplantation in sickle cell anemia?
- Is cord blood better than haploidentical donor for patients without an HLA matched donor?

#### Coagulation Disorders

- Pregnancy complications and thrombophilia – Reality or myth?
- Is there a rationale to change to new oral anti-coagulants in patients receiving Coumadin?

#### Iron Deficiency - Overload

- Is there still a role for oral iron therapy?
- Is there a rationale for iron chelation therapy in minimal residual disease?

### CML

- When generic imatinib becomes more available, should initial therapy be with imatinib or second generation tyrosine-kinase inhibitors?
- Should therapy be changed in patients with CML in chronic phase and “suboptimal” response after 6 months?

### CLL

- Is minimal residual disease a therapy end-point?
- Are imaging techniques needed in the routine evaluation of newly diagnosed patients with CLL?

### Acute Leukemia / MDS

- Should patients with RAEB or oligoblastic AML receive induction chemotherapy prior to allogeneic transplantation?
- Should patients with AML / ALL receive prophylactic antibiotics and antifungal agents?
- Should all patients with non Ph+ ALL undergo transplantation in first CR?

### Myelofibrosis

- Patients responding to Ruxolitinib should not be considered for allogeneic transplantation?

### Lymphoma

- Should therapy be changed in patients with DLBCL if PET scan remain positive after 2 (or 4) courses of treatment?
- Should autologous transplantation be offered to all patients with Peripheral T Cell Lymphoma after induction therapy?

### Hodgkin's lymphoma

- Should Brentuxumab be moved to upfront therapy?

### Myeloma

- Patients with “high risk” myeloma who do not benefit from autologous transplant should be considered for allogeneic transplant?
- Should bisphosphonates be continued indefinitely after chemotherapy is initiated?



info@comtecmed.com  
www.comtecmed.com

#### Headquarters and Administration:

53 Rothschild Boulevard  
PO Box 68  
Tel Aviv 6100001, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: info@comtecmed.com

#### Comtec Spain:

Bailén, 95-97  
pral. 1. a - 08009  
Barcelona, Spain  
Tel: +34-93-2081145  
Fax: +34-93-4579291  
Email: spain@comtecmed.com

#### Comtec Asia:

Suite 405, Universal Center Building  
175 Xiang Yang Road South  
Shanghai 200031, China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: china@comtecmed.com